Trysari Sudiro
Acute Care · Long Beach, CANPI 1396432399
Payments from drug & device makers
Across 62 payments — averaging $36.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$397
- AstraZeneca$326
- Johnson & Johnson$312
- Bayer$120
- Tempus AI, Inc$118
- Seagen Inc.$100
- plus $870 from 20 others
What the payments were for
- Food & beverage$1,86483%
- Education$37817%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $397 |
| AstraZeneca | 5 | $326 |
| Johnson & Johnson | 8 | $312 |
| Bayer | 1 | $120 |
| Tempus AI, Inc | 2 | $118 |
| Seagen Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 2 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Beone Medicines USA, Inc. | 3 | $99 |
| Incyte Corporation | 3 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $80 |
| AbbVie | 2 | $54 |
| Lilly USA, LLC | 2 | $50 |
| Chiesi USA, Inc. | 2 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $23 |
| Novartis | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Caris MPI, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,242 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $9,788 |
| Gabapentin | 27 | $299 |
| Lidocaine Hcl ViscousLidocaine Hcl | 16 | $293 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $214 |
| Ondansetron Hcl | 23 | $194 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 17 | $130 |
| LoperamideLoperamide Hcl | 12 | $117 |
| Lorazepam | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other acute care in Long Beach
- Melissa DodsonLong Beach$12K
- Cindy PetersLong Beach$7K
- Eunice ChanLong Beach$6K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.